Portfolio Strategy

Tier 1:

Well Established Targets Validated by Marketed or Clinical Therapeutics

Tier 2:

Known, GI-Associated Targets That Require New Approaches to Access Effectively and Safely

Tier 3:

Novel GI Biology Pathways, Target Discovery and Validation

These market opportunities range from orphan and rare indications to those with ‘blockbuster’ potential. We are strategically approaching these indications in order to reach patients who will clearly benefit from oral and targeted versions of such biopharmaceutical products that can drive our programs to rapid clinical validation.

Creating True Value to Healthcare Through Oral Biopharmaceuticals

Enhanced Therapeutic
Efficacy

  • Immunology & Inflammation

    Direct access to submucosal GI target biology;
    access local and systemic targets

  • Hepatologic & Metabolic Diseases

    Oral route could provide pharmacological benefits akin to non-pathological state

More Effective Chronic Disease Management & Cost of Care

  • Increased Compliance & Convenience

    • Non-invasive and painless
    • Reduced visits to Doctors’ offices
    • Improved compliance lowers hospitalization rates
  • Lower Cost of Care

    • Disrupts entire needle/syringe device manufacturing and disposal chain
    • Benefits from interval-based dosing vs sustained release
    • Preferred choice/tier in formularies

Biologic Life Cycle & Market Extension

  • Multi-$B biologics franchises are losing patent protection and facing increased competition
  • Differentiation for, or against, biosimilars (‘biobetters’)
  • High potential for market expansion due to preference for pills vs. injections